Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low on Friday . The stock traded as low as GBX 37 and last traded at GBX 39.60, with a volume of 7358 shares changing hands. The stock had previously closed at GBX 41.
Faron Pharmaceuticals Oy Price Performance
The company’s 50-day moving average price is GBX 41.64 and its 200-day moving average price is GBX 54.31. The company has a quick ratio of 1.09, a current ratio of 0.84 and a debt-to-equity ratio of -133.35. The firm has a market cap of £80.34 million, a price-to-earnings ratio of -1.79 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
